Eletriptan HydrobromideRelpax
Recommended NeurologyAuthority RequiredSecond-line line
Acute treatment of migraine attacks in patients where attacks in the past have usually failed to respond to analgesics.
2
Submissions
2010–10
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Mar 2010 Recommended Treat migraine attack
Access path
- TGA registered · Relpax
TGA label narrower than the PBS population
- Mar 2010Recommended · restricted
Listing: Authority Required (Streamlined) → Authority Required
- Mar 2010Recommended · restricted
Listing: Authority Required (Streamlined) → Authority Required
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Cost minimisation analysis; no ICER calculated
Based on the evidence overall the PBAC accepted the flat pricing structure proposed in the submission with eletriptan 40 mg and 80 mg to be priced the same as sumatriptan 50 mg. PBAC · 2010
Decision context
PopulationPatients with migraine attacks where attacks in the past have usually failed to respond to analgesics.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2010 | Recommended · restricted | sumatriptan | — | RCT · OS | PFS | DFS | ORR | QoL | Surrogate | Cost-minimisation | Other | null |
| Mar 2010 | Recommended · restricted | sumatriptan | — | RCT · headache response |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients whose past migraine attacks have usually failed to respond to analgesics; TGA label has no such treatment-failure prerequisite.